HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PF-04254644

Protein Kinase Inhibitor

Also Known As:

6-(S)-1-(-(6-(1 methyl-1H-pyroazol-4-yl)-(1,2,4)triazolo(4,3-b) pyridazin-3-yl-ethyl)quinoline)

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - PF-04254644: 2

Experts

1.	Aguirre, Shirley: 1 article (12/2012)
2.	Hirakawa, Brad: 1 article (12/2012)
3.	Hu, Wenyue: 1 article (12/2012)
4.	Jessen, Bart: 1 article (12/2012)
5.	Lee, Michelle: 1 article (12/2012)
6.	Aguirre, Shirley A: 1 article (04/2010)
7.	Blasi, Eileen R: 1 article (04/2010)
8.	Bobrowski, Walter: 1 article (04/2010)
9.	Collette, Walter: 1 article (04/2010)
10.	Heyen, Jonathan R: 1 article (04/2010)

Related Diseases

1.	Cardiotoxicity 04/01/2010 - "Data suggest that the decreased cardiac function and cardiotoxicity are likely due to inhibition of multiple PDEs by PF-04254644." 12/01/2012 - "These data suggest that cardiotoxicity of PF-04254644 was probably due to activation of c-AMP signaling, and possibly subsequent disruption of intracellular calcium and oxidative stress signaling pathways. "
2.	Fibrosis (Cirrhosis) 04/01/2010 - "Echocardiographic evaluations revealed an increase in heart rate (HR) and contractility after the first dose with PF-04254644 and myocardial fibrosis correlated with decreased cardiac function after repeat dosing. "

Related Drugs and Biologics

1.	Calcium
2.	Adenosine Monophosphate (AMP)
3.	diethylstilbestrol monophosphate (PDES)